Has Delta killed the herd immunity dream?
As the Delta variant continues its global surge, experts are questioning whether the long-held goal of achieving herd immunity from Covid-19 through vaccination is still viable
Slow Covid vaccination to cost global economy $2.3 tn: study
The slow rollout of coronavirus vaccines will cost the global economy $2.3 trillion in lost output, according to the Economist Intelligence Unit
G20 nervous over Delta threat to economic recovery
As healthcare systems brace for damage inflicted by the quick-spreading Delta variant, G20 finance ministers have warned that it could also slow global economic recovery
Scientists seek Covid protection boost for people with weakened immunity
How effective are Covid vaccines if your immune system is compromised by HIV, cancer or a recent organ transplant?
Covid-19: How vaccines work against the Delta variant
The Delta variant of the coronavirus, first identified in India, is a cause for global concern with studies showing it is more contagious and resistant to vaccines than other forms of Covid
EMA chief urges worldwide vaccine access, after G7 vow
The head of the European Medicines Agency told AFP that all countries must have access to coronavirus vaccines, as G7 leaders pledged one billion doses for poor nations
The European Covid certificate, a user’s guide
The EU will launch its digital Covid certificate on July 1. How will it use data on vaccinations, tests and immunity to usher in a return to summer tourism and travel across the European Union?
The WTO waiver battle over Covid jab IP rights
Sudden US backing for a global waiver on patent protections for Covid-19 vaccines offers hope to poor nations struggling for doses -- but big pharma thinks the notion misguided
Contagious and concerning: What we know about Covid-19 variants
Fast-spreading coronavirus variants have ignited global concern over whether existing vaccines will be able to protect the world from a virus that is constantly mutating
AstraZeneca: Who is using the jab, and who isn’t
The AstraZeneca vaccine's rollercoaster ride has taken another twist with a growing list of countries restricting its use over "very rare" blood clots